Harvard Bioscience三季度营收2220万美元同比增8%：净亏损260万美元，重申全年营收增3%至5%指引
Harvard Bioscience于2026年11月10日在马萨诸塞州霍利斯顿公布截至2026年9月30日的第三季度业绩。第三季度营收为2220万美元，上年同期为2060万美元，同比增长8%。
第三季度毛利为1230万美元，上年同期为1200万美元，毛利率为55.4%，上年同期为58.4%。经调整毛利为1270万美元，经调整毛利率为57.1%。
第三季度净亏损为260万美元，上年同期净亏损为120万美元。2026年前九个月营收为6570万美元，上年同期为6280万美元。
公司总裁兼首席执行官John Duke称，这是连续第二个季度实现强劲同比增长。公司重申2026年全年营收同比增长3%至5%的指引。
（来源：Harvard Bioscience）
Harvard Bioscience Third-Quarter Revenue Grows 8 Percent to $22.2 Million, With a $2.6 Million Net Loss, and Full-Year Guidance Reaffirmed
Harvard Bioscience announced financial results for the third quarter ended September 30, 2026, in Holliston, Massachusetts, on November 10, 2026. Third-quarter revenue was $22.2 million, compared with $20.6 million a year earlier, an increase of 8 percent.
Gross profit was $12.3 million, compared with $12.0 million a year earlier, and gross margin was 55.4 percent, compared with 58.4 percent. Adjusted gross profit was $12.7 million and adjusted gross margin was 57.1 percent.
The net loss for the quarter was $2.6 million, compared with a net loss of $1.2 million a year earlier. Revenue for the first nine months of 2026 was $65.7 million, compared with $62.8 million a year earlier.
President and Chief Executive Officer John Duke said the quarter was the second consecutive quarter of strong year-over-year growth. The company reaffirmed full-year 2026 revenue guidance of 3 percent to 5 percent year-over-year growth.
(Source: Harvard Bioscience)
来源：Harvard Bioscience
发布：GSM·美国（发布链接）
图片来源：图：实验室研究人员工作中（资料图）。照片：CC0，经 Wikimedia Commons。 / Photo: Researchers at work in a laboratory (file photo). CC0, via Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
